Dr Patrick Vermersch discusses teriflunomide’s role in the treatment of multiple sclerosis, the focus of his article recently published in European Neurological Review.
View his article here.
Speaker disclosures: Consultant and/or support for research from: Novartis, Biogen, Sanofi,
Teva, Servier, Roche and Celgene.
Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June 2017.
Share this Video
Related Videos In Multiple Sclerosis
Nele Handwerker: Living with MS – living life to the full
Ms Nele Handwerker is living with multiple sclerosis (MS), and is a patient advocate. She joins us for World Brain day and shares the story of her MS diagnosis. Nele discusses strategies and resources that she believes could help improve quality of life for those living with MS. Touch Medical Media is sharing educational resources […]
Barbara Willekens, EAN 2022: Predictors of disease progression and outcome in multiple sclerosis – Highlights
Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors and outcomes in MS and related disorders. Questions: How does cognitive impairment predict physical […]
Melinda Magyari, EAN 2022: Real-world evidence for disease-modifying therapies in multiple sclerosis
Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of real-world data, how ‘big data’ can help physicians understand treatment characteristics, and the future impact […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!